Unicycive Therapeutics (NASDAQ:UNCY) Earns “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage currently has a $9.00 price target on the stock. Separately, Guggenheim initiated coverage on Unicycive Therapeutics in a report on Monday, April 21st. They issued a “buy” rating and a $6.00 […]
HC Wainwright reiterated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage currently has a $9.00 price target on the stock. Separately, Guggenheim initiated coverage on Unicycive Therapeutics in a report on Monday, April 21st. They issued a “buy” rating and a $6.00 […]
